Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 15,508,510 | 11,830,030 | 8,447,178 | 4,096,697 | 14,643,260 |
| Depreciation Amortization | 3,328,075 | 2,571,372 | 1,317,642 | 540,413 | 2,770,515 |
| Accounts receivable | 165,480 | N/A | N/A | N/A | -1,040,955 |
| Accounts payable and accrued liabilities | 396,365 | N/A | N/A | N/A | 469,800 |
| Other Working Capital | 386,676 | -2,604,728 | -1,775,463 | -2,317,991 | 1,492,340 |
| Other Operating Activity | -1,753,066 | 5,661,566 | 1,954,332 | 1,150,671 | -794,600 |
| Operating Cash Flow | $18,032,040 | $17,458,240 | $9,943,689 | $3,469,790 | $17,540,360 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,536,104 | 1,588,550 | 1,542,142 | 1,132,751 | 777,635 |
| PPE Investments | -9,105,196 | -6,531,942 | -4,271,424 | -1,893,844 | -6,838,780 |
| Net Acquisitions | 152,006 | N/A | N/A | N/A | -11,913,630 |
| Purchase Of Investment | -34,065 | -35,235 | -30,268 | -16,227 | -113,970 |
| Sale Of Investment | 4,542 | 1,723 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -4,537,912 | -714,879 | -422,534 | -164,240 | -601,025 |
| Other Investing Activity | -4,537,911 | -714,880 | -422,534 | -164,241 | -601,035 |
| Investing Cash Flow | $-11,984,520 | $-5,691,784 | $-3,182,084 | $-941,560 | $-18,689,780 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 15,735,150 | 11,480,500 | 11,042,160 | 3,860,919 | 11,511,700 |
| Debt Repayment | -11,989,060 | -12,220,280 | -11,694,820 | -1,697,715 | -918,575 |
| Common Stock Repurchased | -210,143 | -217,361 | -211,115 | -195,847 | -2,926,245 |
| Dividend Paid | -7,836,918 | -8,106,086 | -5,338,710 | -2,120,734 | -6,400,300 |
| Other Financing Activity | 0 | 2 | -1 | 922,513 | -5 |
| Financing Cash Flow | $-4,300,971 | $-9,063,225 | $-6,202,486 | $769,136 | $1,266,575 |
| Exchange Rate Effect | -110,068 | -130,448 | -136,282 | -12,135 | 65,975 |
| Beginning Cash Position | 2,370,167 | 2,451,573 | 2,381,125 | 2,208,920 | 2,086,840 |
| End Cash Position | 4,006,650 | 5,024,354 | 2,803,963 | 5,494,152 | 2,269,975 |
| Net Cash Flow | $1,636,483 | $2,572,781 | $422,838 | $3,285,231 | $183,135 |
| Free Cash Flow | |||||
| Operating Cash Flow | 18,032,040 | 17,458,240 | 9,943,689 | 3,469,790 | 17,540,360 |
| Capital Expenditure | -9,105,196 | -6,531,942 | -4,271,424 | -1,893,844 | -6,838,780 |
| Free Cash Flow | 8,926,844 | 10,926,298 | 5,672,265 | 1,575,946 | 10,701,580 |